Comparative Pharmacology
Head-to-head clinical analysis: ENPRESSE 21 versus ORTHO NOVUM 7 7 7 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENPRESSE 21 versus ORTHO NOVUM 7 7 7 21.
ENPRESSE-21 vs ORTHO-NOVUM 7/7/7-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; suppresses gonadotropin release via estrogen-progestin negative feedback, preventing ovulation; alters cervical mucus and endometrial lining to inhibit sperm penetration and implantation.
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
ENPRESSE-21 (ethinyl estradiol/norethindrone acetate) is an oral contraceptive. One tablet (0.035 mg ethinyl estradiol/0.5 mg norethindrone acetate) by mouth once daily for 21 days, followed by 7 placebo days.
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
None Documented
None Documented
Terminal elimination half-life is 8-10 hours; this supports once-daily dosing and reaches steady state within 2-3 days.
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Renal excretion of unchanged drug accounts for approximately 30-40% of the dose; hepatic metabolism accounts for the remainder, with metabolites eliminated in bile and feces.
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive